We are live on ! Find out more
KTTA icon

Pasithea Therapeutics

26 hedge funds and large institutions have $7.6M invested in Pasithea Therapeutics in 2026 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 5 increasing their positions, 6 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

40% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 5

16% more capital inflows, than outflows

Capital inflows: $2.36M | Capital outflows: $2.03M

4% more funds holding

Funds holding: 25 → 26 (+1)

17% less repeat investments, than reductions

Existing positions increased: 5 | Existing positions reduced: 6

21.17% less ownership

Funds ownership: 67.31% → 46.14% (-21%)

Holders
26
Holders Change
+1
Holders Change %
+4%
% of All Funds
0.32%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
5
Reduced
6
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

KTTA Hedge Fund Activity: Q3 2026 in Review

26 of the 8,184 institutional investors tracked by Wall St. Rank reported a position in Pasithea Therapeutics (KTTA) for Q3 2026, worth a combined $7.6M — down 12% from $8.66M a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new KTTA positions and 5 closed out — a net gain of 2 holders — while 5 added to existing stakes and 6 trimmed.

The largest buyer was Stonepine Capital Management, adding an estimated $288K. The largest seller was Opaleye Management, exiting entirely with an estimated $1.06M sold.

  • 26 institutional investors held Pasithea Therapeutics (KTTA) as of Q3 2026, up from 25 in Q2 2026.
  • Funds reported $7.6M of Pasithea Therapeutics stock for Q3 2026, down 12% quarter-over-quarter.
  • 7 funds opened new Pasithea Therapeutics positions in Q3 2026 and 5 closed out, a net change of +2 holders.
  • The largest Pasithea Therapeutics buyer in Q3 2026 was Stonepine Capital Management, an estimated $288K added.
  • The largest Pasithea Therapeutics seller in Q3 2026 was Opaleye Management, an estimated $1.06M sold.

Based on aggregated 13F filings for Q3 2026.